Trial Profile
Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs TBX 1400 (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions
- Sponsors Taiga Biotechnologies
- 06 Oct 2020 Planned initiation date changed from 1 Aug 2020 to 1 Aug 2021.
- 09 Mar 2020 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 09 Mar 2020 Planned primary completion date changed from 1 Feb 2023 to 1 Feb 2024.